NZ592764A - Compound having tafia inhibitory activity - Google Patents
Compound having tafia inhibitory activityInfo
- Publication number
- NZ592764A NZ592764A NZ592764A NZ59276409A NZ592764A NZ 592764 A NZ592764 A NZ 592764A NZ 592764 A NZ592764 A NZ 592764A NZ 59276409 A NZ59276409 A NZ 59276409A NZ 592764 A NZ592764 A NZ 592764A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- inhibitory activity
- tafia inhibitory
- tafia
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008278302 | 2008-10-29 | ||
| PCT/JP2009/068526 WO2010050525A1 (ja) | 2008-10-29 | 2009-10-28 | ＴＡＦＩａ阻害活性を有する化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592764A true NZ592764A (en) | 2012-08-31 |
Family
ID=42128884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592764A NZ592764A (en) | 2008-10-29 | 2009-10-28 | Compound having tafia inhibitory activity |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110213143A1 (xx) |
| EP (1) | EP2361910A4 (xx) |
| JP (1) | JPWO2010050525A1 (xx) |
| AU (1) | AU2009310841A1 (xx) |
| CA (1) | CA2741783A1 (xx) |
| NZ (1) | NZ592764A (xx) |
| WO (1) | WO2010050525A1 (xx) |
| ZA (1) | ZA201103269B (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078424A1 (es) * | 2009-09-17 | 2011-11-09 | Taisho Pharmaceutical Co Ltd | Derivados de dihidroimidazoquinolina con actividad inhibitoria de tafia, composiciones farmaceuticas que los contienen y su uso como agentes terapeuticos o profilacticos para enfermedades tromboticas |
| EP2548872B1 (en) | 2010-03-18 | 2016-09-28 | Daiichi Sankyo Company, Limited | Cyclopropanecarboxylic acid derivative |
| ES2643132T3 (es) | 2010-03-18 | 2017-11-21 | Daiichi Sankyo Company, Limited | Derivado de imidazol cicloalquilo sustituido |
| EP2638016B1 (en) * | 2010-11-11 | 2014-10-01 | Sanofi | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives |
| EP3013823B1 (en) | 2013-06-24 | 2017-11-01 | Merck Patent GmbH | Imidazole compounds as modulators of fshr and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (sv) | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| SE9901573D0 (sv) | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| BR0014615A (pt) * | 1999-09-14 | 2002-06-18 | Meiji Seika Kaisha | Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b |
| HRP20030103A2 (en) | 2000-08-17 | 2003-04-30 | Pfizer | Substituted imidazoles as tafia inhibitors |
| WO2003013526A1 (en) | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| SE0103272D0 (sv) | 2001-09-28 | 2001-09-28 | Astrazeneca Ab | Chemical compounds |
| MXPA04005940A (es) | 2002-01-22 | 2004-09-13 | Pfizer | Acidos 3-(imidazolil)-2-aminopropanoicos. |
| IL162677A0 (en) | 2002-01-22 | 2005-11-20 | Pfizer | 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| EP2204373A1 (en) | 2002-03-21 | 2010-07-07 | Bayer Schering Pharma Aktiengesellschaft | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors |
| SE0201837D0 (sv) | 2002-06-14 | 2002-06-14 | Astrazeneca Ab | Chemical compounds |
| DE102004020186A1 (de) | 2004-04-22 | 2005-11-17 | Aventis Pharma Deutschland Gmbh | Heterocyclylessigsäuren als Inhibitoren von TAFla |
| DE102005049385A1 (de) | 2005-10-15 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Imidazolderivate als Inhibitoren von TAFIa |
| HRP20150514T1 (hr) * | 2006-12-06 | 2015-09-11 | Sanofi | DERIVATI SULFAMIDA KAO INHIBITORI TAFIa |
-
2009
- 2009-10-28 JP JP2010535827A patent/JPWO2010050525A1/ja not_active Withdrawn
- 2009-10-28 WO PCT/JP2009/068526 patent/WO2010050525A1/ja not_active Ceased
- 2009-10-28 CA CA2741783A patent/CA2741783A1/en not_active Abandoned
- 2009-10-28 EP EP09823635A patent/EP2361910A4/en not_active Withdrawn
- 2009-10-28 NZ NZ592764A patent/NZ592764A/xx not_active IP Right Cessation
- 2009-10-28 US US13/126,685 patent/US20110213143A1/en not_active Abandoned
- 2009-10-28 AU AU2009310841A patent/AU2009310841A1/en not_active Abandoned
-
2011
- 2011-05-05 ZA ZA2011/03269A patent/ZA201103269B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110213143A1 (en) | 2011-09-01 |
| AU2009310841A1 (en) | 2010-05-06 |
| EP2361910A1 (en) | 2011-08-31 |
| CA2741783A1 (en) | 2010-05-06 |
| ZA201103269B (en) | 2012-07-25 |
| EP2361910A4 (en) | 2012-08-01 |
| JPWO2010050525A1 (ja) | 2012-03-29 |
| WO2010050525A1 (ja) | 2010-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201000473A (en) | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | |
| TW200740776A (en) | N-phenylbenzotriazolyl c-kit inhibitors | |
| TN2011000280A1 (en) | Benzothiazole derivatives as anticancer agents | |
| MY195209A (en) | Partially Saturated Nitrogen-Containing Heterocyclic Compound | |
| MX2012002528A (es) | Agente terapeutico para trastornos del estado de animo. | |
| MY158982A (en) | Heterocyclic compound | |
| AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
| IL189694A0 (en) | Biphenyl derivatives and their use in treating hepatitis c | |
| PH12014502396A1 (en) | Nitrogenated heterocyclic compound | |
| EA201290397A1 (ru) | 1,3,4-оксадиазол-2-карбоксамидное соединение | |
| WO2009026166A3 (en) | Antiinfective flavonol compounds and methods of use thereof | |
| TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
| WO2007109459A3 (en) | Pyridines and pyridine n-oxides as modulators of thrombin | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| WO2009074247A8 (de) | Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel | |
| WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
| MY162440A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| NZ592764A (en) | Compound having tafia inhibitory activity | |
| WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| MX357774B (es) | Derivado de benzodioxol y metodo de preparacion y uso del mismo. | |
| UA99840C2 (ru) | Замещенные циклопентаны, которые имеют простагландиновую активность | |
| UA99745C2 (xx) | Похідні діоксоантраценсульфонату$производные диоксоантраценсульфоната | |
| WO2006127379A3 (en) | Par2-modulating compounds and their use | |
| WO2009018551A3 (en) | Therapeutic compounds | |
| MX2012002529A (es) | Agente terapeutico para trastornos de ansiedad. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Patent lapsed |